KFF puts current US GLP-1 use at 12% of adults
KFF's March 2026 tracking poll finds 12% of US adults currently use a GLP-1 drug and another 6% used one in the past, but the poll still does not break down use by brand.
About 12% of US adults say they are currently using a GLP-1 medication, and another 6% say they have used one in the past, according to KFF's Health Tracking Poll conducted February 24 to March 2, 2026 [1]. The poll surveyed 1,343 US adults and has a margin of sampling error of plus or minus 3 percentage points for the full sample [1].
The survey question asked adults whether they are currently using or have ever used a GLP-1 drug "to lose weight or treat a chronic condition such as diabetes or heart disease." The question named several brands as examples, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity [1]. Ozempic, Wegovy, and Rybelsus are semaglutide, while Mounjaro and Zepbound are tirzepatide.
Despite naming these brands in the question wording, the published topline does not break down the 12% current-use figure by which specific drug people are taking [1]. That means the poll cannot say what share of current users are on tirzepatide products like Mounjaro or Zepbound versus semaglutide products like Ozempic or Wegovy, or any other GLP-1 medication. This is described as a standing gap in US polling on GLP-1 use.
The topline document lists prior tracking dates for the same question, including November 2025 and May 2024, suggesting KFF has asked a similar question in earlier waves, though the source provided here does not include the numeric results for those earlier months [1].
The same poll also found that 59% of adults say they are very or somewhat worried about affording prescription drug costs for themselves and their families, up from 55% in February 2024 [1]. Separately, 43% of adults said they had either not filled a prescription, cut pills in half or skipped doses, or used an over-the-counter drug instead of a prescription because of cost in the past 12 months, compared with 33% in May 2025 [1].
Why it matters for patients
A finding that roughly one in eight US adults currently uses a GLP-1 drug, with another one in sixteen having used one before, points to how widespread these medications have become across the country [1]. But because the poll does not separate results by brand, patients and clinicians cannot tell from this data alone whether growth is concentrated in tirzepatide products, semaglutide products, or spread evenly across both. That gap matters for anyone trying to understand market trends, insurance coverage patterns, or supply questions tied to a specific drug rather than the GLP-1 class as a whole.
The cost-related findings in the same poll are relevant context for GLP-1 users specifically, since these drugs are often expensive and not always covered by insurance. With 59% of adults worried about affording prescription drugs and 43% reporting some cost-driven change in how they take medication, patients on GLP-1 therapies are likely affected by the same affordability pressures found across the broader prescription drug market [1].
What happens next
The source material does not indicate whether KFF plans to publish a brand-by-brand breakdown of GLP-1 use in a future release, or whether this gap will persist in the next tracking poll. It is not yet known when or whether that data will become available.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.